Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277636 | 1.00 | TDP1 (0.33) | TDP1OPRL1L3MBTL3 | |
| SCHEMBL83552 | 1.00 | TDP1 (0.33) | TDP1OPRL1L3MBTL3 | |
| Hydrochloric Acid SCHEMBL10326141 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Hydrochloric Acid SCHEMBL628075 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Hydrochloric Acid SCHEMBL13583563 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Hydrochloric Acid SCHEMBL15191249 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| Water SCHEMBL28597949 | 0.97 | TDP1 (0.32) | TDP1OPRL1 | |
| SCHEMBL7795040 | 0.85 | — | — | |
| SCHEMBL661220 | 0.83 | TDP1 (0.42) | TDP1L3MBTL3 | |
| SCHEMBL613375 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50776-E1 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-20240391881-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | ORIGIANT PHARMACEUTICAL CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| EP-4410787-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | Origiant Pharmaceutical Co., Ltd (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-9126982-B2 | Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9126982-B2 | Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| WO-2015003958-A1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014068443-A1 | SPLICEOSTATIN ANALOGS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2008065500-A2 | HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | TDP1 276/4885OPRL1 4063/4885L3MBTL3 682/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | TDP1 276/4885OPRL1 4063/4885L3MBTL3 682/4885 |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | TDP1 3128/4885OPRL1 741/4885L3MBTL3 4878/4885 |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | TDP1 2250/4885OPRL1 3261/4885L3MBTL3 943/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | TDP1 276/4885OPRL1 4063/4885L3MBTL3 682/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | TDP1 847/4885OPRL1 4082/4885L3MBTL3 2455/4885 |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | TDP1 2813/4885OPRL1 1798/4885L3MBTL3 3757/4885 |
| US-12098154-B2 | Inhibitors of cyclin-dependent kinases | CDK3, CDK13, CDK1 | TDP1 1233/4885OPRL1 3910/4885L3MBTL3 481/4885 |
| US-20240391881-A1 | PHARMACEUTICAL USE AND PREPARATION METHOD FOR SUBSTITUTED HETEROARYL PHTHALAZINE DERIVATIVE | NLRP3, NLRP1, NOD1 | TDP1 2179/4885OPRL1 2321/4885L3MBTL3 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.